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Exercise-Based Cardiac Rehabilitation Reduces the 
Risk of Cardiovascular (CV) Mortality and Hospital 
Admission and Improves Quality of Life in Patients 
With Coronary Heart Disease 
Meta-analyses of exercise-based cardiac rehabilitation (CR) 
studies (n=63) comprising 14,486 participants with median 
follow-up of 1 year indicated that CR led to a reduction in 
CV mortality (relative risk - RR: 0.74) and the risk of hospital 
admissions (RR: 0.82). There was no significant effect on 
mortality, MI, or revascularization. The majority of studies (14 
of 20) showed higher levels of health-related quality of life 
following exercise-based CR compared with control subjects 
(Anderson L et al, J Am Coll Cardiol 2016;67:1-12).
Coronary CT Angiography (CCTA), Applied Early 
in Suspected Acute Coronary Syndrome (ACS), is 
Safe and Associated with Less Outpatient Testing 
and Lower Costs. However, in the Era of High-
Sensitivity (hs)-Troponins, it does not Identify more 
Patients with Significant CAD Requiring Coronary 
Revascularization, nor does it Shorten Hospital Stay 
or Allow for More Immediate Discharge from the 
Emergency Department (ED)
Among 500 patients (age 54±10 years, 47% women) with 
symptoms suggestive of an ACS at the ED, there was no dif-
ference in the primary endpoint (22 or 9% patients underwent 
coronary revascularization within 30 days in the CCTA group 
and 17 or 7% in the standard care group; p= NS). Discharge 
from the ED was not more frequent after CCTA (65% vs 59%, 
p= NS), and length of stay was similar (6.3 h in both groups; 
p= NS). The CCTA group had lower direct medical costs (€337 
vs €511, p <0.01) and less outpatient testing (10 or 4% vs 26 or 
10%, p <0.01). There was no difference in incidence of unde-
tected ACS (Dedic A et al, J Am Coll Cardiol 2016; 67:16-26).
Cost-Effectiveness of Transcatheter Aortic Valve 
Implantation (TAVI) with a Self-Expanding Prosthesis 
vs Surgical Aortic Valve Replacement (AVR): TAVI 
in Patients at High Risk for Complications with AVR 
Provides Important Incremental Health Benefits at 
Reasonable Incremental Costs and is an Acceptable 
Value for the U.S. Health Care System
Relative to AVR, TAVI reduced initial length of stay an 
average of 4.4 days, decreased the need for rehabilitation 
services at discharge, and resulted in superior 1-month qual-
ity of life. Index admission and projected lifetime costs were 
higher with TAVI than with AVR (differences $11,260 and 
$17,849 per patient, respectively), whereas TAVI was projected 
to provide a lifetime gain of 0.32 quality-adjusted life-years 
(QALY; 0.41 LY) with 3% discounting. Lifetime incremental 
cost-effectiveness ratios were $55,090 per QALY gained and 
$43,114 per LY gained. N.B.: mean procedure costs: $37,920 
for TAVI & $14,258 for AVR (Reynolds MR et al, J Am Coll 
Cardiol 2016;67:29-38).
5-Year Follow-Up of SYNTAX: for Patients with 
Complex Coronary Disease, CABG Conferred a Lower 
Rate of Cardiac Death After Than PCI, and Patients 
who Had PCI with First-Generation DES were at 
Higher Risk of Fatal MI Than Those Who Had CABG 
In this cohort, there were 97 deaths after CABG and 123 
deaths after PCI at 5 years. After CABG, 49.4% of deaths 
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were cardiovascular (CV), with the greatest cause being heart 
failure, arrhythmia, or other causes (24.6%), whereas after 
PCI, the majority of deaths were CV (67.5%) and as a result 
of MI (29.3%). All-cause death rates were not significantly 
different between CABG and PCI (11.4% vs 13.9%; p=NS), 
whereas there were significant differences for CV (5.8% vs 
9.6%; p=0.008) and cardiac death (5.3% vs 9%; p=0.003), 
which were caused primarily by a reduction in MI-related death 
with CABG compared with PCI (0.4% vs 4.1%; p <0.0001). 
Treatment with PCI vs CABG was an independent predictor 
of cardiac death (hazard ratio: 1.55; p=0.045). The difference 
in MI-related death was mostly seen in patients with diabetes, 
3-vessel disease, or high SYNTAX scores (Milojevic M et al, 
J Am Coll Cardiol 2016;67:42-55).
TRANSLATE-ACS: after AMI and PCI, Patients Who 
Develop Bleeding During Dual Antiplatelet Therapy 
(DAPT) Exhibit Worse Health Status and Quality 
of Life After 6 Months Proportionate to Severity of 
Bleeding 
Of 9,290 patients with AMI treated with PCI, bleeding 
events on contemporary DAPT occurred as follows: any 
Bleeding Academic Research Consortium (BARC) bleeding: 
24.2%; BARC 1: 9.1%; BARC 2: 13.8%; BARC 3: 1.1%; 
BARC 4: 0.03%; and BARC 5: 0%. Those who experienced 
any BARC bleeding had lower scores across all quality of 
life (QOL) domains. Any BARC bleeding was independently 
associated with 6-month QOL score (p <0.0001) in a stepwise 
fashion with increasing BARC severity (Amin AP et al, J Am 
Coll Cardiol 2016;67:59-65.66: 2173-2184).
MESA (Multi-Ethnic Study of Atherosclerosis): 
Nontraditional CV Risk Markers (Coronary Artery 
Calcium-CAC Score, Ankle–Brachial Index-ABI, 
hsCRP Levels, and Family History - FH) were each 
Independently Associated with Atherosclerotic CV 
Disease (ASCVD) Beyond Traditional Risk Factors
Of 5,185 participants not prescribed statins at baseline 
(mean age 61 years; 53% women, 9.8% diabetes, 13.6% cur-
rent smokers), after 10 years of follow-up, 320 (6.2%) ASCVD 
events occurred. CAC score, ABI, and FH were independent 
predictors of ASCVD events. CAC score modestly improved 
the discriminative ability of the risk estimator compared with 
other nontraditional risk markers (Yeboah J et al, J Am Coll 
Cardiol 2016;67:139-147).
Infective Endocarditis (IE): A Systematic Search Can 
Identify the Source of Bacteremia in 3/4 of Patients 
With IE, and in >1/3 of Cases, Additional Potential 
Portals of Entry (POE) Can Be Found That Pose a Risk 
for Future Infections
The POEs of the present IE episodes were identified in 
74% of the 318 included patients. The most frequent POE was 
cutaneous (40%). It was mainly (62% of cutaneous POEs) 
associated with health care and with intravenous drug use. 
The second most frequent POE was oral or dental (29%). A 
dental infectious focus was more often involved (59%) than 
a dental procedure (12%). POEs were gastrointestinal in 23% 
of patients. Colonic polyps were found in half of patients 
and colorectal adenocarcinomas in 14%. The authors advise 
the systematic performance of stomatologic examinations in 
patients with IE and performance of colonoscopy in patients 
≥50 years of age or at high risk for colorectal cancer (Delahaye 
F et al, J Am Coll Cardiol 2016;67:151-158).
ATRIA Study: Among Patients With Diabetes and 
Atrial Fibrillation (AF), the Duration of Diabetes is a 
More Important Predictor of Ischemic Stroke Than 
Glycemic Control 
Among 2,101 diabetic patients (40% with duration <3 
years and 60% ≥3 years at baseline) and 1,933 included in 
the hemoglobin A1c (HbA1c) analysis (46% with HbA1c 
<7%, 36% at 7%-8.9%, & 19% ≥9%), duration of diabetes 
≥3 years was associated with an increased rate of ischemic 
stroke compared with duration <3 years (hazard ratio - HR: 
1.74). The increased stroke rate was observed in older (age 
≥75 years) and younger (age <75 years) patients. Neither poor 
glycemic control (HbA1c ≥9%, HR: 1.04) nor moderately 
increased HbA1c (7-8.9%, HR: 1.21) were significantly as-
sociated with an increased rate of ischemic stroke compared 
with patients who had HbA1c <7% (Ashburner JM et al, J 
Am Coll Cardiol 2016;67:239-247).
SMILE Trial: in Multivessel Non–ST-Segment 
Elevation Myocardial Infarction (NSTEMI) Patients, 
Complete 1-Stage Coronary Revascularization is 
Superior to Multistage PCI Regarding Major Adverse 
Cardiovascular / Cerebrovascular Events (MACCE) 
Among 584 patients randomly assigned to 1-stage (1S-PCI) 
or multistage PCI (MS-PCI), the occurrence of the primary 
endpoint (MACCE) was significantly lower in the 1-stage 
group (1S-PCI: n=36-13.6% vs. MS-PCI: n=61-23.2%; hazard 
ratio - HR: 0.549; p=0.004). The 1-year rate of target vessel 
revascularization was significantly higher in the MS-PCI 
group (1S-PCI: n=22-8.3% vs MS-PCI: n=40-15.2%; HR: 
0.522; p=0.01). Analysis of cardiac death and MI showed no 
significant differences (Sardella G et al, J Am Coll Cardiol 
2016; 67:264-272). 
IMPROVE-IT: In Addition to Reducing First Events 
in Patients After an ACS, Combination Therapy With 
Ezetimibe Plus Simvastatin Also Reduced Total Events 
Compared With Simvastatin Alone 
During a median 6-year follow-up, among 18,144 patients, 
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there were 9,545 total cardiovascular (CV) events (56% first 
and 44% subsequent events), which were significantly reduced 
by 9% with ezetimibe/simvastatin vs placebo/simvastatin 
(incidence-rate ratio - RR: 0.91; p=0.007), as was the compos-
ite endpoint of CV death, MI, or stroke (RR: 0.88; p=0.002). 
The reduction in total events was driven by decreases in total 
nonfatal MI (RR: 0.87; p=0.004) and total nonfatal stroke 
(RR: 0.77; p=0.005) (Murphy SA et al, J Am Coll Cardiol 
2016;67:353-361).
MADIT-CRT Trial: Relative Wall Thickness (RWT) 
is Inversely Related to the Risk of Ventricular 
Tachycardia (VT) in Patients with Systolic Heart 
Failure (HF) and LBBB / CRT-D Conferred an Increase 
in RWT and Reduction in VT Risk 
Relative wall thickness (RWT), defined as 2 times posterior 
wall thickness divided by the left ventricular (LV) diastolic 
diameter, is a measure of LV geometry and may be a marker 
for adverse events in patients with LV dysfunction. In 1,260 
patients with mild HF and LBBB, RWT was the most power-
ful echocardiographic measure for estimating the risk of VT. 
Patients with low RWT (<0.24) had 83% (p <0.001) increased 
risk for VT and 68% (p <0.001) increase in VT risk or death 
(VT/death). Each 0.01-unit decrease in RWT was associated 
with 12% (p <0.001) and 10% (p <0.001) increases in the 
risk of VT and VT/death, respectively. Cardiac resynchro-
nization therapy with defibrillator (CRT-D) was associated 
with a greater increase in RWT compared with ICD at 1 year 
(4.6±6.8% vs 1.5±2.7%; p <0.001), and every 10% increase in 
RWT in CRT-D patients was associated with 34% (p=0.027) 
and 36% (p=0.009) reductions in the risk of subsequent VT 
and VT/death, respectively (Biton Y et al, J Am Coll Cardiol 
2016;67:303-312).
CYCLE Trial: IV Cyclosporine A (CsA) Immediately 
Before Primary Coronary Angioplasty Within 6 h 
from Symptom Onset in Patients With STEMI did not 
Improve Markers of Myocardial Injury, Ventricular 
Remodeling, or Clinical Outcomes, Indicating that 
this Strategy did not Prevent or Reduce Reperfusion-
Related Injury 
In 410 patients, aged 63±12 years, with large STEMI 
committed to primary PCI, randomly assigned within 6 h 
of symptom onset to 2.5 mg/kg IV CsA (n=207) or control 
(n=203) groups, time from symptom onset to first ante-grade 
flow was 180±67 min; a median of 5 ECG leads showed ST-
segment deviation; ~50% of MIs were anterior. ST-segment 
resolution ≥70% was found in 52% of CsA patients and 49% 
of controls (p=NS). Median hs-cTnT on day 4 was 2,160 ng/l 
in CsA and 2,068 ng/l in controls (p=NS). The 2 groups did 
not differ in LV ejection fraction on day 4 and at 6 months. 
Infarct site did not influence CsA efficacy. There were no 
acute allergic reactions or nonsignificant excesses of 6-month 
mortality (5.7% CsA vs 3.2% controls, p=NS) or cardiogenic 
shock (2.4% CsA vs 1.5% controls, p=NS) (Ottani F et al; J 
Am Coll Cardiol 2016;67:365-374). 
Chlorthalidone: Low-Dose Chlorthalidone, 6.25 mg/d, 
is More Effective than Hydrochlorothiazide (HCTZ), 
12.5 mg/d, in Reducing Daytime, Nighttime, and Mean 
24-h Ambulatory Blood Pressure Over 4 - 12 Weeks 
with only 6.3% Hypokalemia and Can be Prescribed 
as Initial Therapy for Treatment of Hypertension, 
Whereas Low-Dose HCTZ Should no Longer be Used 
Chlorthalidone 6.25 mg/d (n=16) was compared with 
HCTZ 12.5 mg/d (n=18), or HCTZ-CR 12.5 mg (n=20) over 
12-weeks in 54 patients with stage 1 hypertension. All 3 treat-
ments significantly (p <0.01) lowered office blood pressure 
(BP) at weeks 4 and 12 from baseline. At weeks 4 and 12, 
significant reductions in systolic and diastolic 24-h ambulatory 
and nighttime BP (p <0.01) were observed with chlorthalidone 
but not with HCTZ. At weeks 4 (p=0.015) and 12 (p=0.020), 
nighttime systolic ambulatory BP was significantly lower in the 
chlorthalidone group than in the HCTZ group. The HCTZ-CR 
group showed a significant (p <0.01) reduction in 24-h BP. All 
3 treatments were generally safe and well tolerated (Pareek 
AK et al, J Am Coll Cardiol 2016;67:379-389). 
REACH Registry: Pulse pressure (PP), Arising as a 
Consequence of Arterial Stiffness in Patients With 
Atherosclerosis, is a Marker of Cardiovascular Disease 
Burden and Identifies Patients at Risk for Ischemic 
Events According to a Large, International Registry of 
>45,000 Participants With Established or at High Risk 
for Arterial Disease 
In a 45,087 cohort (aged 68±10 years, 35% women, 
81% treated for hypertension), with mean blood pressure of 
138±19/79±11 mmHg, rendering a mean PP of 49±16 mmHg, 
on univariate analysis, increasing PP quartile was associated 
with worse outcomes (p <0.05). After adjusting for gender, 
age, current smoking status, history of hypercholesterolemia, 
history of diabetes, aspirin use, statin use, blood pressure drug 
use, and mean arterial pressure, PP quartile was still associated 
with all outcomes except all stroke and cardiovascular death (p 
<0.05) (Selvaraj S et al, J Am Coll Cardiol 2016;67:392-403).
In Patients With Degenerative Mitral Regurgitation 
(MR) Undergoing Surgical Repair With Annuloplasty, 
Recurrences are Low/≥Mild Early Post-Operative MR 
is Associated With Adverse Ventricular Remodeling 
and Higher Rates of Recurrent MR, Need for 
Reoperation, and Death Than in Patients With None-
To-Trivial Early Post-Operative MR 
Among 1,218 patients (mean age 64±13 years, mean ejec-
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tion fraction 63±9%, 864 - 71% men), the 15-year incidence of 
recurrent MR (MR ≥2) was 13.3%, mitral reoperation 6.9%, 
and overall mortality 44%. Repair before 1996 independently 
predicted MR recurrence (hazard ratio: 1.52). Additional 
determinants were: age, mild intraoperative residual MR, 
anterior leaflet prolapse, bileaflet prolapse, perfusion time 
>90 min, and lack of annuloplasty. Recurrence of ≥ moderate 
MR was associated with adverse left ventricular remodeling 
and increased likelihood of late death (hazard ratio: 1.72). 
After 1996, MR recurrence decreased markedly following the 
first year after intervention (Suri RM et al, J Am Coll Cardiol 
2016;67:488-498).
THERMOCOOL VT Trial: Radiofrequency Ablation 
of VT is Effective in Preventing Recurrent VT and ICD 
Shocks, Reducing Hospitalizations, and Improving 
Quality of Life for ≥3 Years
In patients (n=249; mean age 67.4 y) with sustained mono-
morphic ventricular tachycardia (VT) associated with coronary 
disease, the cardiovascular-specific adverse events rate was 
3.9% (9 of 233) with no strokes. Noninducibility of targeted 
VT was achieved in 75.9% of patients. Post-ablation median 
hospitalization was 2 days. At 6 months, 62% (114 of 184) of 
patients had no sustained monomorphic VT recurrence; the 
proportion of patients with ICD shocks decreased from 81.2% 
to 26.8% (p <0.0001); the frequency of VT in ICD patients 
with recurrences was reduced by ≥50% in 63.8% of patients; 
and quality of life improved (p <0.001). Patient-reported VT 
remained steady for 1, 2, and 3 years at 22.7%, 29.8%, and 
24.1%, respectively. Amiodarone use and hospitalization de-
creased at 1-3 years (Marchlinski FE et al, J Am Coll Cardiol 
2016;67:674-683). 
SORT OUT IV: Rate of Major Adverse Cardiovascular 
Events (MACE) at 5 Years is Lower in Patients Treated 
with Everolimus-Eluting Coronary Stents (EES) than 
in those Treated with Sirolimus-Coated Stents (SES), 
Attributable Largely to a Lower Rate of Late Stent 
Thrombosis 
Among 2,771 patients at 5-years, MACE occurred in 14% 
and 17.4% in the EES and SES groups, respectively (hazard 
ratio - HR: 0.80, p=0.02). The MACE rate did not differ sig-
nificantly within the first year (HR: 0.96, p=0.79), but from 
years 1 through 5, the MACE rate was lower with EES (HR: 
0.71; p=0.006). Definite stent thrombosis was lower with EES 
(0.4%) than with SES (2%; HR: 0.18), with a lower risk of 
very late definite stent thrombosis in the EES group (0.2% vs 
1.4%, respectively; HR: 0.16). When censoring the patients at 
the time of stent thrombosis, we found no significant differ-
ences between the 2 stent groups for MACE rates (HR: 0.89; 
p=0.23), target lesion revascularization (HR: 0.90, p=0.55), 
and MI (HR: 0.93; p=0.72) (Jensen LO et al, J Am Coll Cardiol 
2016;67:751-762). 
Patients With PFO Who Develop Cryptogenic Ischemic 
Stroke Face Relatively Low Rates of Recurrent 
Cerebral Ischemic Events During Medical Therapy 
With or Without Device Closure, But Pooled Results 
of Randomized Trials Show Lower Stroke Rates With 
Percutaneously Implanted Device Closure Than With 
Medical Therapy Alone
According with data on 2 devices (STARFlex, NMT 
Medical, Inc., Boston, MA & Amplatzer, AGA Medical/St. 
Jude Medical, St. Paul, MN) evaluated in 3 trials in 2,303 
patients, PFO closure was not significantly associated with 
the primary composite outcome (stroke, TIA, or death). The 
difference became significant after covariate adjustment (haz-
ard ratio - HR: 0.68; p=0.049). For stroke, all comparisons 
were statistically significant (HRs 0.58, p=0.043). In analyses 
limited to the 2 disc occluder device trials, the effect of closure 
was not significant for the composite outcome, but was for 
the stroke outcome (HR: 0.39; p=0.013). Subgroup analyses 
did not identify significant heterogeneity of treatment effects. 
AF was more common in closure patients (Kent DM et al, J 
Am Coll Cardiol 2016;67:907-917). 
Patients With LQT3 Respond Incompletely to 
Beta-Blockers and Face an Unfavorable Prognosis / 
Mexiletine Exerted Effective Antiarrhythmic Effects 
in this Cohort, Representing a Genotype-Specific 
Treatment for an Inherited Arrhythmogenic Substrate 
In 34 LQT3 patients (19 or 56% male; median age 22 years 
at beginning of treatment with mexiletine; median QTc interval 
before therapy 509 ms; median duration of oral mexiletine 3 
years; average daily dose 8±0.5 mg/kg), mexiletine signifi-
cantly shortened QTc (by 63±6 ms; p <0.0001) and reduced 
the percentage of patients with arrhythmic events (from 22% 
to 3%; p=0.031), the mean number of arrhythmic events per 
patient (from 0.43±0.17 to 0.03±0.03; p=0.027), and the annual 
rate of arrhythmic events (from 10.3% to 0.7%; p=0.0097) 
(Mazzanti A et al, J Am Coll Cardiol 2016;67:1053-1058). 
PEGASUS-TIMI 54 Trial: In Patients With Prior MI 
on Extended Dual Antiplatelet Therapy, Ticagrelor 
60 mg bid Provides a Degree of Platelet Inhibition 
Comparable to that Achieved with 90 mg bid, which 
May Explain the Nearly Equivalent Efficacy of these 
Doses for Prevention of Recurrent Ischemic Events
In 180 patients mean pre- and post-dose plasma levels of 
ticagrelor were 35% and 38% lower, respectively, with 60 
mg vs 90 mg bid. Both doses achieved high levels of platelet 
inhibition pre- and post-dose, with numerically slightly more 
variability with 60 mg: pre-dose PRU values were 59±63 and 
47±43 for ticagrelor 60 and 90 mg, respectively (p=NS). High 
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platelet reactivity (PRU >208) was rare with the 60-mg pre-
dose and was absent post-dose. Platelet reactivity pre- and 
post-dose, as measured by light transmittance aggregometry 
or vasodilator-stimulated phosphoprotein assays, was numeri-
cally but not significantly lower with 90 mg than with 60 mg. 
Aspirin response was not affected by either dose (Storey RF 
et al, J Am Coll Cardiol 2016;67:1145-1154.).
PREDICTS Study: Most Patients with Severe LV 
Dysfunction in the Acute Phase of MI Exhibit 
Improvement in LV Function 90 Days Later / Prior MI, 
Early VF or Cardiac Arrest, Peak Serum Troponin, 
and EF Early After Presentation are Predictors of 
Later Myocardial Recovery 
Among patients with ejection fraction (EF) ≤35% at the 
time of MI (n= 231), 43% had persistent EF ≤35%, 31% had 
an EF of 36-49%, and 26% had an EF ≥50% at 3 months. 
Predictors for EF recovery to >35%, identified in a separate 
cohort (n=236) included EF at presentation, length of stay, 
prior MI, lateral wall motion abnormality at presentation, and 
peak troponin. The model that best predicted recovery of EF 
to ≥50% included EF at presentation, peak troponin, prior MI, 
and presentation with ventricular fibrillation or cardiac arrest. 
After predictors were transformed into point scores, the lowest 
point scores predicted a 9% and 4% probability of EF recovery 
to >35% and ≥50%, respectively, whereas profiles with the 
highest point scores predicted an 87% and 49% probability 
of EF recovery to >35% and ≥50%, respectively (Brooks GC 
et al, J Am Coll Cardiol 2016;67:1186-1196). 
BRUISE CONTROL INFECTION Study: Strategies to 
Reduce Pocket Hematomas in Device Implants, Such as 
Continuing Oral Anticoagulants Rather Than Bridging 
with Heparin, May Reduce Long-Term Infection Risk 
Among 659 patients the 1-year device-related infection 
rate was 2.4% (16/659). Infection occurred in 11% of patients 
(7/66) with previous clinically significant pocket hematoma 
(CSH) and in 1.5% (9/593) without CSH. CSH was the only 
independent predictor and was associated with a >7-fold in-
creased risk of infection (hazard ratio: 7.7; p<0.0001). Empiric 
antibiotics upon development of hematoma did not reduce 
long-term infection risk (Essebag V et al, J Am Coll Cardiol 
2016; 67:1300-1308). 
CHAMPION PHOENIX Trial: Cangrelor Reduced 
the Odds of Major Adverse Cardiovascular Events and 
Stent Thrombosis in Women and Men and Appeared to 
Offer Greater Net Clinical Benefit Than Clopidogrel 
Cangrelor, an IV ADP receptor antagonist leading to potent 
and reversible inhibition of platelet aggregation, given in a 
randomized way with clopidogrel to 11,145 patients undergo-
ing elective or urgent PCI (3051 or 28% women) reduced the 
odds of the primary end point (death, MI, revascularization, 
stent thrombosis) by 35% in women (odds ratio - OR, 0.65); 
and by 14% in men (OR, 0.86) compared with clopidogrel. 
Cangrelor reduced the odds of stent thrombosis by 61% in 
women (OR, 0.39) and 16% in men (OR, 0.84). The odds of 
severe bleeding were similar in women and men treated with 
cangrelor (0.3% vs 0.2% in women; 0.1% vs 0.1%, for men) vs 
clopidogrel. Cangrelor increased the odds of moderate bleed-
ing in women (0.9% vs 0.3%, P=0.02), but not in men (0.2% 
vs 0.2%, P=NS). The net clinical benefit favored cangrelor 
in both women (OR, 0.68) and men (OR, 0.87) (O’Donoghue 
ML et al, Circulation 2016;133: 248-255). 
National Trends in the Use of Cardiac 
Resynchronization Therapy (CRT) With or Without 
ICD: The Majority (86%) of Patients in this US Cohort 
Underwent Implantation of CRT-D 
Among 311,086 admissions for CRT implant, CRT-D was 
the most common device type (86.1%), including in patients 
≥75 years of age with ≥5 comorbidities (75.5%). Multivariate 
predictors of CRT-D implant included: prior ventricular ar-
rhythmia (rate ratio - RR, 1.14), ischemic heart disease (RR, 
1.11), male gender (RR, 1.10), black race (RR, 1.06), and 
Northeast geographic region (RR, 1.06). There was significant 
interhospital variation in the use of CRT-D (10–90 percentile 
range, 73%–98% CRT-D) (Lindvall C et al, Circulation 2016; 
133: 273-281). 
Sugar-Sweetened Beverage (SSB) Consumption is 
Associated With Change of Visceral Adipose Tissue 
(VAT) Over 6 Years of Follow-Up 
The quantity and quality of abdominal adipose tissue were 
measured using computed tomography in 1003 participants 
(mean age 45.3 years, 45% women) at baseline and 6 years 
later. Higher SSB intake was associated with greater change in 
VAT volume (P trend<0.001). VAT volume increased by 658 
cm3, 649 cm3, 707 cm3, and 852 cm3 from nonconsumers (none 
to <1 serving/mo) to non-daily (1 serving/mo to <1 serving/
week, 1 serving/week to 1 serving/d) to daily (≥1 serving/d) 
consumers. Higher SSB intake was also associated with greater 
decline of VAT attenuation (P trend=0.007); however, the as-
sociation became nonsignificant after additional adjustment 
for VAT volume change. In contrast, diet soda consumption 
was not associated with change in abdominal adipose tissue 
(Ma J et al, Circulation 2016;133:370-7). 
Aerobic Interval Training (AIT) Reduces the Burden  
of Atrial Fibrillation (AF) in the Short Term
Patients with nonpermanent AF were randomized to AIT 
(n=26) consisting of four 4-minute intervals at 85% to 95% 
of peak heart rate 3 times a week for 12 weeks or to a control 
group (n=25) continuing regular exercise habits. Mean time 
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in AF measured by an implanted loop recorder increased from 
10.4% to 14.6% in the control group and was reduced from 
8.1% to 4.8% in the exercise group (P=0.001). AF symptom 
frequency (P=0.006) and AF symptom severity (P=0.009) 
were reduced after AIT. AIT improved V˙ O2 peak, left atrial 
and ventricular ejection fraction, quality-of-life, and lipid 
values compared with the control group. There was a trend 
toward fewer cardioversions and hospital admissions after AIT 
(Malmo V et al, Circulation 2016; 133: 466-473). 
The S-Wave in Lead I: A New Electrocardiographic 
Marker of Sudden Death in Brugada Syndrome (BS) 
During follow-up (48±38 months) of 347 patients (78.4% 
male; age 45±13.1 years) with spontaneous type 1 BS but no 
history of cardiac arrest (91.1% initially asymptomatic, 5.2% 
with history of atrial fibrillation - AF, and 4% with history 
of syncope), 276 (79.5%) patients remained asymptomatic, 
39 (11.2%) developed syncope, and 32 (9.2%) developed 
ventricular fibrillation (VF) / sudden cardiac death (SCD). 
Patients who developed VF/SCD had a lower prevalence of 
SCN5A gene mutations (p=0.009) and a higher prevalence 
of positive electrophysiological study results (p <0.0001), 
a family history of SCD (p=0.03), and AF (p <0.0001). The 
most powerful marker for VF/SCD was a significant S-wave 
(≥0.1 mV and/or ≥40 ms) in lead I. In multivariate analysis, 
the duration of S-wave in lead I ≥40 ms (hazard ratio: 39.1) 
and AF (hazard ratio: 3.7) were independent predictors of 
VF/SCD during follow-up (Calo L et al, J Am Coll Cardiol 
2016;67:1427–1440). 
Pooled Analysis: In Patients With Brugada Syndrome 
(BS), Arrhythmias Induced With Programmed 
Ventricular Stimulation are Associated With Future 
Arrhythmia Risk / Induction With Fewer Extrastimuli 
is Associated With Higher Risk / However, Clinical 
Risk Factors are Important Determinants of 
Arrhythmia Risk, and Lack of Induction does not 
Necessarily Portend Low Risk, Particularly in Patients 
With High-Risk Clinical Features 
Analysis of 8 studies comprising 1312 patients with BS ex-
periencing 65 cardiac events (median follow-up, 38.3 months) 
indicated a total of 527 patients with inducible arrhythmias. 
Induction was associated with cardiac events during follow-up 
(hazard ratio, 2.66; P <0.001), with the greatest risk observed 
among those induced with single or double extrastimuli. 
Annual event rates varied by syncope history, presence of 
spontaneous type 1 ECG pattern, and arrhythmia induction. 
The lowest risk occurred in individuals without syncope and 
with drug-induced type 1 patterns (0.23% for no induced 
arrhythmia with up to 2 extrastimuli; 0.45% for induced ar-
rhythmia), and the highest risk occurred in individuals with 
syncope and spontaneous type 1 pattern (2.55% for no induced 
arrhythmia; 5.60% for induced arrhythmia) (Sroubek J et al, 
Circulation 2016; 133: 622-630). 
Brugada Syndrome is Common in Women (42% in 
this Database) / Clinical Presentation is Less Severe 
than Men, With More Asymptomatic Status and 
Less Spontaneous Type I ECG and Prognosis is More 
Favorable, With an Event Rate of 0.7% Year. However, 
Women With Sudden Cardiac Death (SCD) or Previous 
Sinus Node Dysfunction (SND) are at Higher Risk of 
Arrhythmic Events 
Among 228 women presenting with spontaneous or drug-
induced Brugada type I ECG (age 41.5±17.3 years; clinical 
presentation with SCD in 6 or 2.6%, syncope in 51 or 22.4% 
and 171 or 75% asymptomatic) compared with 314 men with 
the same diagnosis, spontaneous type I ECG was less common 
(7.9% vs 23.2%, p <0.01) and less ventricular arrhythmias were 
induced during programmed electrical stimulation (5.5% vs 
22.3%, p <0.01). An ICD was implanted in 64 women (28.1%). 
During follow-up of 73.2±56.2 months, 7 patients developed 
arrhythmic events, constituting an event rate of 0.7% per year 
(as compared with 1.9% per year in men, p=0.02). Presentation 
as SCD or SND was risk factor significantly associated with 
arrhythmic events (hazard risk - HR 25.4 and 9.1) (Sieira J et 
al, Heart 2016; 102:452-458). 
WOSCOPS: In High-Risk Men With Elevated LDL 
Cholesterol but Without a History of MI, Statin 
Therapy for 5 Years was Associated With a Legacy 
Benefit, With Improved Survival and a Substantial 
Reduction in CV Disease Outcomes Over 20-Years
Among 6595 men, randomized to receive pravastatin 40 
mg/d or placebo for an average of 4.9 years, analysis of major 
incident events over 20 years indicated that men allocated to 
pravastatin had reduced all-cause mortality (hazard ratio-HR, 
0.87; P=0.0007), attributable mainly to a 21% decrease in 
cardiovascular (CV) death (HR, 0.79; P=0.0004). There was 
no difference in non-CV or cancer death rates between groups. 
Cumulative hospitalization event rates were lower in the statin-
treated arm: by 18% for any coronary event (P=0.002), by 
24% for myocardial infarction (MI) (P=0.01), and by 35% for 
heart failure (P=0.002). There were no significant differences 
between groups in hospitalization for non-CV causes (Ford I 
et al, Circulation 2016;133:1073-1080). 
Two-Year Outcomes of Surgery for Severe Ischemic 
Mitral Regurgitation (MR): No Significant Difference 
Between Mitral-Valve Repair and Replacement in LV 
Reverse Remodeling or Survival / MR Recurred More 
Frequently in the Repair Group, With More Heart-
Failure–Related Adverse Events and CV Admissions
In patients (n=251) with severe ischemic MR, randomized 
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to mitral-valve (MV) repair or replacement, at 2 years, LV 
end-systolic volume (LVESV) was 52.6±27.7 ml/m2 with MV 
repair and 60.6±39.0 ml/m2 with MV replacement. Two-year 
mortality was 19% in the repair and 23.2% in the replacement 
group (hazard ratio, 0.79; P=0.39). The rate of recurrence of 
moderate or severe MR at 2 years was higher in the repair 
than in the replacement group (58.8% vs 3.8%, P <0.001). 
There were no significant between-group differences in seri-
ous adverse events and overall readmissions, but patients in 
the repair group had more serious adverse events related to 
heart failure (P=0.05) and cardiovascular (CV) re-admissions 
(P=0.01). There was a trend toward greater quality of life 
improvement in the replacement group (P=0.07) (Goldstein 
D et al, N Engl J Med 2016; 374:344-353).
The Leadless Intracardiac Transcatheter Pacemaker, 
Compared to Historical Conrols, Met the Prespecified 
Safety and Efficacy Goals / It Had a Safety Profile 
Similar to that of a Transvenous System With Low and 
Stable Pacing Thresholds
The Micra transcatheter pacemaker was successfully im-
planted in 719 of 725 patients (99.2%). The primary safety 
end point (freedom from major complications) was 96% (P 
<0.001 for the comparison with the safety performance goal 
of 83%); there were 28 major complications in 25 of 725 
patients, and no dislodgements, all fewer compared to the 
control patients (hazard ratio, 0.49; P=0.001). The rate of the 
primary efficacy end point (percentage of patients with low 
and stable pacing capture thresholds at 6 months, i.e. ≤2.0 V 
at a pulse width of 0.24 ms and an increase of ≤1.5 V from the 
time of implantation) was 98.3% (P <0.001 for the comparison 
with the efficacy performance goal of 80%) among 292 of 297 
patients with paired 6-month data (Reynolds D et al, N Engl 
J Med 2016; 374:533-541). 
Coronary Artery Surgery: The Administration of 
Preoperative Aspirin Resulted in Neither  
a Lower Risk of Death or Thrombotic  
Complications Nor a Higher Risk of Bleeding 
Compared With Placebo
Patients (n=2100) who were scheduled to undergo coronary 
artery surgery and were at risk for perioperative complications 
were randomly assigned to receive 100 mg of aspirin (n=1047) 
or placebo (n=1053) preoperatively. A primary outcome event 
(death and thrombotic complications, i.e. nonfatal myocar-
dial infarction, stroke, pulmonary embolism, renal failure, 
or bowel infarction within 30 days after surgery) occurred in 
202 patients in the aspirin group (19.3%) and in 215 patients 
in the placebo group (20.4%) (relative risk, 0.94; P=NS). 
Major hemorrhage leading to reoperation occurred in 1.8% 
of patients in the aspirin group and in 2.1% of patients in the 
placebo group (P=NS), and cardiac tamponade occurred at 
rates of 1.1% and 0.4%, respectively (P=0.08) (Myles PS et 
al, N Engl J Med 2016; 374:728-737). 
ACT I Trial: In Asymptomatic Patients With Severe 
Carotid Stenosis Who were not at High Risk for 
Surgical Complications, Stenting was Noninferior To 
Endarterectomy at 1 Year / At 5 Years, there were no 
Significant Differences Between the Study Groups in 
Rates of Stroke and Survival 
Among 1453 asymptomatic patients <79 years with se-
vere carotid stenosis, stenting with embolic protection was 
noninferior to endarterectomy with regard to the primary 
composite end point (death, stroke, or MI within 30 days) 
(event rate, 3.8% and 3.4%, respectively; P=0.01 for non-
inferiority). The rate of stroke or death within 30 days was 
2.9% in the stenting group and 1.7% in the endarterectomy 
group (P=NS). From 30 days to 5 years after the procedure, 
the rate of freedom from ipsilateral stroke was 97.8% in 
the stenting group and 97.3% in the endarterectomy group 
(P=NS), and overall survival rates were 87.1% and 89.4%, 
respectively (P=0.21). The cumulative 5-year rate of stroke-
free survival was 93.1% in the stenting group and 94.7% in 
the endarterectomy group (P=NS) (Rosenfield K et al, N Engl 
J Med 2016; 374:1011-1020).
CREST 10-Year Results: No Significant Difference 
Between Patients Who Underwent Stenting and Those 
With Endarterectomy in the Risk of Periprocedural 
Stroke, MI, or Death and Subsequent Ipsilateral Stroke 
Among 2502 patients, there was no significant difference 
in the rate of the primary composite end point (stroke, MI or 
death) between the stenting group (11.8%) and the endar-
terectomy group (9.9%) over 10 years of follow-up (hazard 
ratio - HR, 1.10). Postprocedural ipsilateral stroke over the 
10-year follow-up occurred in 6.9% of the patients in the stent-
ing group and in 5.6% of those in the endarterectomy group; 
the rates did not differ significantly between the groups (HR, 
0.99). No significant between-group differences with respect 
to either end point were detected when symptomatic patients 
and asymptomatic patients were analyzed separately (Brott 
DG et al, N Engl J Med 2016; 374:1021-1031). 
Warning Symptoms Frequently Occur Before 
Sudden Cardiac Arrest (SCA), But Most are Ignored 
/ Emergent Medical Care Call Was Associated With 
Survival in Patients With Symptoms 
Of 839 patients with SCA and comprehensive assessment 
of symptoms (mean age, 52.6 years; 75% men), 430 (51%) had 
warning symptoms (50% of men & 53% of women), mainly 
chest pain and dyspnea. In most symptomatic patients (93%), 
symptoms recurred within the 24 hours preceding SCA. Only 
81 patients (19%) called emergency medical services (EMS) 
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to report symptoms before SCA; these persons were more 
likely to be patients with a history of heart disease (P <0.001) 
or continuous chest pain (P <0.001). Survival when EMS was 
called in response to symptoms was 32.1% compared with 6% 
in those who did not call (P <0.001) (Marijon E et al, Ann 
Intern Med 2016;164:23-29).
VISION study: Among Patients Undergoing  
Non-Cardiac Surgery, Pre-Operative Statin  
Therapy Conferred a Lower Risk of Cardiovascular 
Outcomes at 1 Month 
Among 15,478 patients (≥45 years) having in-patient 
non-cardiac surgery, analysis of a matched population of 
2845 patients (18.4%) treated with a statin and 4492 (29%) 
controls, indicated that the pre-operative use of statins was 
associated with lower risk of the primary outcome, a composite 
of all-cause mortality, myocardial injury after non-cardiac 
surgery (MINS), or stroke at 30 days (relative risk - RR, 
0.83; P=0.007). Statins were also associated with a signifi-
cant lower risk of all-cause mortality (RR, 0.58; P=0.003), 
cardiovascular mortality (RR, 0.42; P=0.004), and MINS 
(RR, 0.86; P=0.02). There were no significant differences 
in the risk of MI or stroke (Berwanger O et al, Eur Heart J 
2016; 37:177-185). 
Effect of Timing of Pre-operative Discontinuation 
of Ticagrelor/Clopidogrel on CABG-Related Major 
Bleeding: Discontinuation 3 Days (vs 5 Days) Before 
Surgery did not Increase the Incidence of Major 
Bleeding Complications with Ticagrelor,  
but Increased the Risk with Clopidogrel 
Among all acute coronary syndrome patients in Sweden on 
dual antiplatelet therapy with aspirin and ticagrelor (n=1266) 
or clopidogrel (n=978) who underwent CABG, the incidence 
of major bleeding complications was 38 and 31%, respectively, 
when ticagrelor/clopidogrel was discontinued <24 h before 
surgery. Within the ticagrelor group, there was no significant 
difference between discontinuation 3–5 or >5 d before surgery 
(odds ratio - OR 0.93, P=NS). In contrast, clopidogrel-treated 
patients had a higher incidence when discontinued 3–5 vs >5 
d before surgery (OR 1.71, P=0.033). The overall incidence 
of major bleeding complications was lower with ticagrelor 
(12.9 vs 17.6%, adjusted OR 0.72, P=0.012) (Hansson EC et 
al, Eur Heart J 2016; 37:189-197). 
Significance of ECG Recording in High Intercostal 
Spaces (HICS) in Patients With Early Repolarization 
Syndrome (ERS): 16% of the Patients Diagnosed 
With ERS Under the Previous Criteria were Actually 
Brugada Syndrome (BS) Patients With Inferolateral  
ER and a Type 1 Brugada Pattern-ECG Only in HICS 
Among 56 patients showing inferolateral early repolari-
zation (ER) in the standard ECG and spontaneous idiopathic 
ventricular fibrillation (VF) who underwent drug provocation 
tests by sodium channel blockade with right precordial ECG 
(V1–V3) recordings in the 2nd–4th intercostal spaces, and 
after 18 patients showing type 1 Brugada pattern-ECG in the 
standard ECG were excluded, 38 patients (34 males, mean 
age; 40.4±13.6 years) were classified into 4 groups: group 
A (n=6; 16%): patients with ER and type 1 Brugada pattern-
ECG only in HICS; group B (n=5; 13%): ERS with non-type 
1 Brugada pattern-ECG only in HICS; group C (n=8; 21%): 
ERS with non-type 1 Brugada pattern-ECG in the standard 
ECG; and group D (n=19; 50%): ERS only, spontaneously or 
after drug provocation test. During follow-up of 9.2±4.6 years, 
the rate of VF recurrence was significantly higher in groups 
A (4/6:67%), B (4/5:80%), and C (4/8:50%) compared with 
D (2/19:11%) (A, B, and C vs D, P <0.05) (Kamakura T et 
al, Eur Heart J 2016; 37:630-637). 
EAST-AF Trial: Short-Term Use of Antiarrhythmic 
Drugs (AAD) for 3 Months Following AF Ablation 
Reduced Recurrent AF During the Treatment Period, 
But it did not Lead to Improved Clinical Outcomes at 
1 Year / Early Arrhythmia Recurrence was Strongly 
Associated With Late Arrhythmia Recurrence 
Among 2038 patients who had undergone radiofrequency 
catheter ablation for paroxysmal, persistent, or long-lasting 
AF, randomly assigned to either 90-day use of AAD (n=1016) 
or control (n=1022) group, those assigned to AAD were as-
sociated with higher event-free rate from recurrent AF when 
compared with the control group during the treatment period 
of 90 days (59 and 52.1%, respectively; hazard ratio - HR 
0.84; P=0.01). However, there was no significant difference 
in the 1-year event-free rates (Kaitani K et al, Eur Heart J 
2016; 37:610-618). 
SEPTAL CRT Study: Septal RV Pacing in CRT 
is Similar to Apical RV Pacing for LV Reverse 
Remodelling at 6 Months With no Difference in the 
Clinical Outcome 
Patients (n=263, age=63.4±9.5 years) were randomly as-
signed to right ventricular septal (RVS) (n=131) vs apical (RVA) 
(n=132) pacing. Left ventricular end-systolic volume (LVESV) 
reduction between baseline and 6 months was not different 
between the two groups. RVS pacing was not non-inferior to 
RVA pacing with regard to LVESV reduction (average dif-
ference = -4.06 mL; P=0.006 with a -20 mL non-inferiority 
margin). The percentage of ‘echo-responders’ defined by 
LVESV reduction >15% between baseline and 6 months was 
similar in both groups (50%) with no difference in the time to 
first heart failure hospitalization or death (P=NS). Procedural 
or device-related serious adverse events occurred in 68 patients 
(RVS=37) with no difference between the two groups (P=NS) 
(Leclercq C et al, Eur Heart J 2016; 37:473-483). 
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BIOSOLVE II: Implantation of the DREAMS 2G 
Absorbable Stent in De-Novo Coronary Lesions is 
Feasible, With Favorable Safety and Performance 
Outcomes at 6 Months
In 123 patients with 123 coronary target lesions receiving 
the novel absorbable stent, at 6 months, mean in-segment late 
lumen loss was 0.27±0.37 mm, and angiographically discern-
able vasomotion was documented in 20 (80%) of 25 patients. 
Intravascular ultrasound showed a preservation of the scaffold 
area with a low mean neointimal area, and optical coherence 
tomography did not detect any intraluminal mass. Target lesion 
failure occurred in 4 (3%) patients: 1 (<1%) died from cardiac 
death, 1 (<1%) had periprocedural MI, and 2 (2%) patients 
needed clinically driven target lesion revascularization. No 
definite or probable scaffold thrombosis was observed (Haude 
M et al, Lancet 2016; 387:31–39). 
Systematic Review and Meta-Analysis: Intensive Blood 
Pressure (BP) Lowering Provided Greater Vascular 
Protection Than Standard Regimens 
Among 44,989 participants (19 trials), 2496 major cardio-
vascular (CV) events were recorded at a mean of 3.8 years. 
Patients in the more intensive BP-lowering group (mean BP 
133/76 mmHg, compared with 140/81 mmHg in the less 
intensive treatment group) had relative risk (RR) reductions 
for major CV events (14%), MI (13%), stroke (22%), albu-
minuria (10%), and retinopathy progression (19%). However, 
more intensive treatment had no clear effects on heart failure 
(15%), CV death (9%), total mortality (9%), or end-stage 
kidney disease (10%). The reduction in major CV events was 
consistent across patient groups, and additional BP lowering 
had a benefit even when systolic BP was <140 mmHg. The 
absolute benefits were greatest in trials in which all enrolled 
patients had vascular or renal disease, or diabetes. Serious 
adverse events associated were only reported by 6 trials and 
had an event rate of 1.2%/year in the intensive vs 0.9% in the 
less intensive treatment group (RR 1.35). Severe hypotension 
was more frequent in the more intensive treatment regimen 
(RR 2.68, p=0.015), but the absolute excess was small (0.3% 
vs 0.1% per person-year for the duration of follow-up) (Xie 
X et al, Lancet 2016; 387:435–443). 
Blood Pressure (BP) Lowering Significantly Reduces 
Vascular Risk Across Various Baseline BP Levels and 
Comorbidities / Results Provide Strong Support for 
Lowering BP to Systolic BPs <130 mmHg and Treating 
Individuals With a History of Cardiovascular (CV) 
Disease, Coronary Disease, Stroke, Diabetes, Heart 
Failure, and Chronic Kidney Disease 
Among 613,815 participants (123 studies) every 10 mmHg 
reduction in systolic BP significantly reduced the risk of major 
CV disease events (relative risk - RR 0.80), coronary disease 
(0.83), stroke (0.73), and heart failure (0.72), which led to 
a significant 13% reduction in all-cause mortality (0.87). 
However, the effect on renal failure was not significant (0.95). 
Similar proportional risk reductions (per 10 mm Hg lower 
systolic BP) were noted in trials with higher and trials with 
lower mean baseline systolic BP (all ptrend >0.05). There was 
no clear evidence that proportional risk reductions in major 
CV disease differed by baseline disease history, except for 
diabetes and chronic kidney disease, for which smaller, but 
significant, risk reductions were detected. β blockers were 
inferior to other drugs for prevention of major CV disease 
events, stroke, and renal failure. Calcium channel blockers 
(CCBs) were superior to other drugs for the prevention of 
stroke. For the prevention of heart failure, CCBs were inferior 
and diuretics were superior to other drug classes (Ettehad D 
et al, Lancet 2016; 387:957–967).
TOTAL Trial, 1-Year Follow-Up: Routine Thrombus 
Aspiration During PCI for STEMI did not Reduce 
Longer-Term Clinical Outcomes and Might be 
Associated With an Increase in Stroke 
Among 10,064 patients (5035 thrombectomy/5029 PCI 
alone), the primary outcome at 1 year occurred in 8% in the 
thrombectomy group and 8% in the PCI alone group. Cardio-
vascular death within 1 year occurred in 4% in each group. 
The key safety outcome, stroke within 1 year, occurred in 
1.2% in the thrombectomy group and 0.7% in the PCI alone 
group (hazard ratio-HR 1.66, p=0·015) (Jolly SS et al, Lancet 
2016; 387(10014):127-135). 
After Eighty Study: In Patients Aged ≥80 Years With 
NSTEMI or Unstable Angina, an Invasive is Superior to 
a Conservative Strategy 
Among patients aged ≥80 years with NSTEMI or unstable 
angina, at a median of 1.53 years, the primary outcome (MI, 
need for urgent revascularization, stroke and death) occurred in 
93/229 (40.6%) patients in the invasive and 140/228 (61.4%) 
patients in the conservative group (hazard ratio - HR 0.53, 
p=0.0001). HRs were 0.52 (p=0.0010) for MI, 0.19 (p=0.0010) 
for need for urgent revascularization, 0.60 (p=NS) for stroke, 
and 0.89 (p=NS) for death. The invasive group had 4 (1.7%) 
major and 23 (10%) minor bleeding complications and the 
conservative group 4 (1.8%) major & 16 (7%) minor bleeding 
complications (Tegn N et al, Lancet 2016;387:1057-1065). 
CNODES Study: In Patients With Diabetes, Incretin-
Based Drugs, Including Dipeptidyl Peptidase 4 (DPP-
4) Inhibitors and Glucagon-Like Peptide 1 (GLP-1) 
Analogues, were not Associated With an Increased Risk 
of Hospitalization for Heart Failure, as Compared With 
Commonly Used Combinations of Oral Antidiabetic 
Drugs
In cohorts including a total of 1,499,650 patients, with 
29,741 hospitalized for heart failure (incidence rate, 9.2 events 
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per 1000 persons per year), the rate of hospitalization for heart 
failure did not increase with the use of incretin-based drugs 
as compared with oral antidiabetic-drug combinations among 
patients with a history of heart failure (hazard ratio - HR, 0.86) 
or among those without a history of heart failure (HR, 0.82). 
The results were similar for DPP-4 inhibitors and GLP-1 ana-
logues (Filion KB et al, N Engl J Med 2016; 374:1145-1154). 
First-In-Man Experience with an Implanted Left-To-
Right Interatrial Shunt Demonstrates Initial Safety and 
Early Beneficial Clinical and Hemodynamic Outcomes 
in Patients with Heart Failure with Reduced Ejection 
Fraction 
An interatrial shunt was successfully implanted in 10 pa-
tients with NYHA class III chronic heart failure with reduced 
ejection fraction with no device-related or procedural adverse 
events during follow-up. Transesophageal echocardiography at 
1 month showed that all shunts were patent, with no thrombosis 
or migration. From baseline to 3 month follow-up, improve-
ments in NYHA classification from class III to class II were 
recorded in 7 (78%) of 9 patients, from class III to class I in 1 
(11%) patient, and no change in 1 (11%) patient; p=0·0004); 
quality of life and 6-minute walk test distance improved. Pul-
monary capillary wedge pressure was reduced from a mean of 
23 mm Hg at baseline to 17 mm Hg at 3 months (p=0.035), 
with no changes in right atrial pressure, pulmonary arterial 
pressure, or pulmonary resistance. No patient was hospitalized 
for worsening heart failure. One (10%) patient was admitted to 
hospital with gastrointestinal bleeding at month 1; one (10%) 
patient died after incessant ventricular tachycardia storm, 
which led to terminal heart failure 2 months post-procedure 
(Del Trigo M et al, Lancet 2016; 387(10025):1290–1297). 
REDUCe Elevated Left Atrial Pressure in Patients  
with Heart Failure (REDUCE LAP-HF) Study 
(Multicenter, Open-Label, Single-Arm, Phase 1  
Trial): Transcatheter Implantation of an Interatrial 
Shunt Device for Heart Failure with Preserved  
Ejection Fraction (HFPEF) is Feasible, Seems to be 
Safe, Reduces Left Atrial Pressure during Exercise,  
and could be a New Strategy for the Management  
of HFPEF
A transcatheter interatrial shunt device (IASD, Corvia 
Medical, Tewkesbury, MA, USA) was implanted in 68 patients 
>40 years of age with symptoms of HFPEF despite pharma-
cological therapy, LVEF >40%, and increased pulmonary 
capillary wedge pressure (PCWP) at rest (>15 mmHg) or 
during exercise (>25 mmHg). IASD placement was success-
ful in 64 patients and seemed to be safe and well tolerated; 
no patient had a peri-procedural or major adverse cardiac or 
cerebrovascular event or need for cardiac surgery for device-
related complications during follow-up. At 6 months, 31 (52%) 
of 60 patients had a reduction in PCWP at rest, 34 (58%) of 
59 had a lower PCWP during exertion, and 23 (39%) of 59 
fulfilled both these criteria. Mean exercise PCWP was lower at 
6 months than at baseline, both at 20 watts workload, despite 
increased mean exercise duration. Sustained device patency at 
6 months was confirmed by left-to-right shunting (Hasenfuss 
G et al, Lancet 2016; 387:1298–1304). 
Important Review and Other Articles 
2015 ACC/AHA/SCAI Focused Update on Primary PCI 
for Patients With STEMI (Levine GN et al, J Am Coll Car-
diol 2016;67:1235-1250), Exercise and cardiovascular events 
(Eijsvogels TMH et al, J Am Coll Cardiol 2016;67:316-329), 
Natriuretic peptide testing in heart failure (Francis GS et al, J 
Am Coll Cardiol 2016;67:330-337), Subcutaneous ICD (Lewis 
GF & Gold MR, J Am Coll Cardiol 2016;67:445-454), Testos-
terone and cardiovascular disease (Kloner RA et al, J Am Coll 
Cardiol 2016;67:545-557), Pulmonary embolism management 
(Konstantinides S et al, J Am Coll Cardiol 2016;67:976-990), 
QRS duration vs morphology in CRT (Poole JE et al, J Am Coll 
Cardiol 2016;67:1104-1117), ICD lead failure and management 
(Swerdlow CD et al, J Am Coll Cardiol 2016;67:1358-1368), 
Surgery for aortic dilatation in bicuspid aortic valves (Hiratzka 
LF et al, Circulation 2016;133:680-686), Acute MI in women 
(Mehta LS et al, Circulation 2016;133: 916-947), Sudden 
death in the young (Ackerman M et al, Circulation 2016;133: 
1006-1026), Combined angiotensin receptor antagonism and 
neprilysin inhibition (Hubers SA & Brown NJ, Circulation 
2016;133:1115-1124), Statin associated autoimmune myopathy 
(Mammen AL, N Engl J Med 2016;374:664-669), Special 
Issue on the 2015 ESC/ERS Guidelines for the diagnosis and 
treatment of pulmonary hypertension (Eur Heart J 2016 Jan; 
37(1)), 2015 ESC Guidelines for the management of ACS 
without persistent ST-segment elevation (Eur Heart J 2016; 
37:267-315), TAVI (Hamm CW et al, Eur Heart J 2016; 37: 
803-810), Catheter ablation of VT (Tanawuttiwat T et al, Eur 
Heart J 2016;37:594-609), Infective endocarditis (Cahill TJ & 
Prendergast BD, Lancet 2016; 387(10021):882–893), Cardiac 
sarcoidosis (Kusano KF & Satomi K, Heart 2016;102:184-
190).
